9783330342835 - open source licensing in biotechnology and pharmaceuticals di balabanian, george (6 risultati)
- Brossura
Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 65,13
EUR 11,69 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Paperback. Condizione: Brand New. 60 pages. 8.66x5.91x0.14 inches. In Stock.
- Brossura
Da: preigu, Osnabrück, Germaniapreigu
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 33,25
EUR 70,00 spedizioneSpedito da Germania a U.S.A.Quantità: 5 disponibili
Taschenbuch. Condizione: Neu. Open Source Licensing in Biotechnology and Pharmaceuticals | George Balabanian | Taschenbuch | 60 S. | Englisch | 2017 | LAP LAMBERT Academic Publishing | EAN 9783330342835 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | An…bieter: preigu.
- Brossura
- Print on Demand
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 35,90
EUR 23,00 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The concept and practical use of open-source, which will be summarily covered, has gone further than any person could have possibly imagined just twenty years ago. A thorough introduction to the concept of open source will be given…. Drawing from the many analogies already proven to be successful in other fields, a compelling case will be made as to why open-source licensing systems would be more beneficial for society than traditional means of distributing goods and knowledge. The pharmaceutical industry is plagued with notoriously high research and development (R&D) costs, unreasonably long and arduous procedural requirements, no or little incentives to focus on developing drugs for rare and neglected diseases - all of which are problems which can be remedied by the concept and application of open-source, which offers the industry a suitable and proper way to meet its future needs. We explore the development and themes surrounding a number of open-source licensing systems and frameworks which have been proposed in the field of biotechnology and pharmaceuticals, with special attention paid to the issues of R&D and rare and neglected diseases, especially in the Global South. 60 pp. Englisch.
- Brossura
- Print on Demand
Da: moluna, Greven, Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 31,27
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: Più di 20 disponibili
Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Balabanian GeorgeGeorge Balabanian is a lawyer, linguist, translator, philologist, and philosopher. He holds numerous academic degrees and is primarily a communicator of ideas - whether in economics, h…istory, game design, multilingua.
- Brossura
- Print on Demand
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 35,90
EUR 60,00 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The concept and practical use of open-source, which will be summarily covered, has gone further than any person could have possibly imagined just twenty years ago. A thorough introduction to the concept of open source will be given. Dr…awing from the many analogies already proven to be successful in other fields, a compelling case will be made as to why open-source licensing systems would be more beneficial for society than traditional means of distributing goods and knowledge. The pharmaceutical industry is plagued with notoriously high research and development (R&D) costs, unreasonably long and arduous procedural requirements, no or little incentives to focus on developing drugs for rare and neglected diseases - all of which are problems which can be remedied by the concept and application of open-source, which offers the industry a suitable and proper way to meet its future needs. We explore the development and themes surrounding a number of open-source licensing systems and frameworks which have been proposed in the field of biotechnology and pharmaceuticals, with special attention paid to the issues of R&D and rare and neglected diseases, especially in the Global South.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 60 pp. Englisch.
- Brossura
- Print on Demand
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 37,20
EUR 60,54 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The concept and practical use of open-source, which will be summarily covered, has gone further than any person could have possibly imagined just twenty years ago. A thorough introduction to the concept of open source will be given. Dra…wing from the many analogies already proven to be successful in other fields, a compelling case will be made as to why open-source licensing systems would be more beneficial for society than traditional means of distributing goods and knowledge. The pharmaceutical industry is plagued with notoriously high research and development (R&D) costs, unreasonably long and arduous procedural requirements, no or little incentives to focus on developing drugs for rare and neglected diseases - all of which are problems which can be remedied by the concept and application of open-source, which offers the industry a suitable and proper way to meet its future needs. We explore the development and themes surrounding a number of open-source licensing systems and frameworks which have been proposed in the field of biotechnology and pharmaceuticals, with special attention paid to the issues of R&D and rare and neglected diseases, especially in the Global South.
